Skip to main content

Table 3 Factors associated with use of specific erectile dysfunction treatments after prostate cancer treatment/management

From: Use of erectile dysfunction treatments after prostate cancer treatment and their perceived impact on men’s sex life: an analysis of patient reported outcome survey data

Factors

Oral Medications

Intracavernosal Injections

Vacuum Pumps

OR

95% CI

P value

OR

95% CI

P value

OR

95% CI

P value

Time post-treatment:

3 months

2.48

1.88–3.27

< 0.001

0.19

0.09–0.40

< 0.001

0.42

0.23–0.78

0.006

6 months

2.10

1.63–2.27

< 0.001

0.84

0.49–1.44

0.530

1.35

0.80–2.27

0.260

12 months

1.00

reference

-

1.00

reference

-

1.00

reference

-

2 years

0.59

0.39–0.87

0.008

1.94

1.00–3.77

0.051

0.38

0.12–1.22

0.104

5 + years

0.21

0.15–0.30

< 0.001

0.76

0.40–1.42

0.386

0.16

0.06–0.42

< 0.001

Age at diagnosis:

< 60 years

1.00

reference

-

1.00

reference

-

1.00

reference

-

60–69 years

0.36

0.24–0.54

< 0.001

0.57

0.28–1.16

0.122

0.45

0.19–1.04

0.062

70–79 years

0.08

0.05–0.13

< 0.001

0.23

0.09–0.58

0.002

0.07

0.02–0.26

< 0.001

≥ 80 years

0.02

0.00–0.05

< 0.001

0.04

0.00–1.03

0.052

   

Treatment received before completing PROMS (yes v no):

Radical prostatectomy

4.33

2.92–6.42

< 0.001

13.8

3.81–49.7

< 0.001

18.0

6.55–49.2

< 0.001

Radiation therapy

0.49

0.32–0.73

0.001

0.95

0.42–2.15

0.897

0.13

0.03–0.54

0.005

Hormone therapy

0.26

0.12–0.58

0.001

0.75

0.18–3.13

0.691

0.71

0.08–6.58

0.765

Observation*

0.69

0.43–1.11

0.125

0.74

0.25–2.22

0.590

0.45

0.10–2.11

0.312

PSA at diagnosis:

<4 ng/mL

1.00

reference

-

1.00

reference

-

1.00

reference

-

4–10 ng/mL

0.58

0.36–0.92

0.020

0.88

0.33–2.32

0.797

0.82

0.26–2.58

0.732

> 10 ng/mL

0.28

0.16–0.49

< 0.001

1.07

0.36–3.24

0.9

1.02

0.27–3.78

0.978

Gleason score:

≤ 6

1.00

reference

-

1.00

reference

-

1.00

reference

-

7

1.48

0.96–2.28

0.076

2.35

0.94–5.89

0.067

2.66

0.58–12.2

0.209

8–10

0.62

0.35–1.10

0.103

1.81

0.57–5.72

0.312

1.58

0.23–10.8

0.640

Geographic location:

Major city/outer urban

1.00

reference

-

1.00

reference

-

1.00

reference

-

Outer Regional

0.96

0.58–1.58

0.869

2.78

1.05–7.35

0.040

2.01

0.70–5.83

0.196

Remote/Very remote

1.33

0.66–2.68

0.426

2.56

0.66–9.90

0.172

Socioeconomic Status (quintiles):

Most disadvantaged Q1

1.00

reference

-

1.00

reference

-

1.00

reference

-

Q2

1.45

0.87–2.41

0.152

0.98

0.33–2.92

0.969

1.78

0.48–6.64

0.392

Q3

1.30

0.76–2.23

0.345

0.73

0.21–2.51

0.620

0.95

0.21–4.33

0.945

Q4

1.68

1.01–2.80

0.047

3.06

1.08–8.68

0.035

1.58

0.41–6.02

0.504

Most advantaged Q5

2.41

1.47–3.93

< 0.001

2.39

0.84–6.81

0.104

1.11

0.29–4.30

0.877

Continence score:

per 10 pt score increase

1.07

1.01–1.13

0.020

1.03

0.92–1.15

0.642

0.99

0.87–1.13

0.933

Body mass index:

Healthy

1.00

reference

-

1.00

reference

-

1.00

reference

-

Overweight

1.52

1.07–2.15

0.018

0.83

0.41–1.68

0.613

1.33

0.51–3.44

0.558

Obese

0.70

0.47–1.05

0.084

0.85

0.43–2.07

0.889

0.95

0.32–2.85

0.929

Smoking status:

Never smoked

1.00

-

-

1.00

reference

-

1.00

reference

-

Past smoker

0.77

0.58–1.01

0.061

0.89

0.50–1.57

0.684

0.74

0.36–1.52

0.415

Current smoker

0.68

0.38–1.21

0.191

1.89

0.68–5.26

0.224

0.36

0.06–2.10

0.256

Depression symptoms

Small-large v none/very small problem

0.48

0.27–0.84

0.011

0.52

0.15–1.76

0.290

2.00

0.52–7.68

0.313

  1. *Observation includes Active surveillance (95%) and watchful waiting (5%)